Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis
Pacing and Clinical Electrophysiology · 2026-08 · 49 (8) · 1086-1099
DOI: 10.1111/pace.70262 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Pacing and Clinical Electrophysiology, online erschienen am 25.04.2026. Verfasst von Abdalhakim Shubietah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Among patients undergoing catheter ablation for atrial fibrillation (AF), it remains uncertain whether peri‐ or post‐ablation use of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduces AF recurrence.
Objectives
We conducted a meta‐analysis of observational studies and randomized controlled trials comparing GLP‐1 RA therapy versus no GLP‐1 RA use on AF recurrence following ablation.
Methods
We systematically searched PubMed, Scopus, Web of Science, and Embase for adult randomized and observational studies. Random‐effects models generated risk ratios (RRs), and heterogeneity was assessed via I 2 . Time‐to‐event outcomes were synthesized using reconstructed individual patient data from Kaplan–Meier curves.
Results
Six studies met the inclusion criteria, with four contributing data for Kaplan–Meier curve reconstruction and five included in the hazard ratio (HR) meta‐analysis. Across four studies ( n = 695; GLP‐1 RA = 295; control = 400), pooled Kaplan–Meier curves showed a lower risk of AF recurrence with GLP‐1 RA therapy (HR 0.53, 95% confidence interval [CI]: 0.38–0.72), with a restricted mean survival time (RMST) advantage of 1.02 months. A random‐effects meta‐analysis of five studies confirmed this benefit (HR 0.78, 95% CI: 0.61–0.99; I 2 = 75%). Pairwise analyses at 12 months demonstrated fewer AF recurrences with GLP‐1 RAs (28.6% vs. 32.9%; RR 0.82, 95% CI: 0.76–0.90; I 2 = 46.9%).
Conclusion
GLP‐1 RA therapy was associated with reduced AF recurrence after ablation, but methodological limitations warrant cautious interpretation. Prospective randomized trials are needed to confirm this potential benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
- Department of Medicine, An-Najah National University, Nablus, Palestine.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Yarmouk University, Irbid, Jordan.
- Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.
ORCID-Profile: Abdalhakim Shubietah, Mohamed S Elgendy, Ameer Awashra, Mohammad Alqudah, Ahmed Emara, Mohamed Abuelazm, Mohammed Mhanna
Zitieren
APA
Shubietah, A., Elgendy, M. S., Awashra, A., Murad, M. R., Alqudah, M., Gowaily, I., Mohamed, A. A., Emara, A., Olumuyide, E., Elbataa, A., Abuelazm, M., & Mhanna, M. (2026). Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis. Pacing and Clinical Electrophysiology, 49(8), 1086-1099. https://doi.org/10.1111/pace.70262
Vancouver
Shubietah A, Elgendy MS, Awashra A, Murad MR, Alqudah M, Gowaily I, et al. Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis. Pacing and Clinical Electrophysiology. 2026;49(8):1086-1099. doi:10.1111/pace.70262
BibTeX
@article{Shubietah2026,
author = {Shubietah, Abdalhakim and Elgendy, Mohamed S and Awashra, Ameer and Murad, Mohamed R and Alqudah, Mohammad and Gowaily, Ibrahim and Mohamed, Ahmed Almahdy and Emara, Ahmed and Olumuyide, Emmanuel and Elbataa, Ahmed and Abuelazm, Mohamed and Mhanna, Mohammed},
title = {Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {8},
pages = {1086--1099},
doi = {10.1111/pace.70262}
}
EUVIMED